CORE 1--TISSUE PROCUREMENT AND GENETICS

核心 1——组织采购和遗传学

• 批准号: 6844130
• 负责人: ROGER E MCLENDON
• 金额: $ 9.73万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6844130
• 关键词: biomedical facility; brain neoplasms; cancer registry /resource; cytogenetics; human therapy evaluation; human tissue; molecular biology information system; neoplasm /cancer genetics; neoplasm /cancer therapy

We hypothesize that a tissue bank organized around an integrated histologic and molecular diagnostic laboratory with all research and clinical information available from a constantly updated database is an essential element to the success of this SPORE. To test this hypothesis we propose the following 4 Specific Aims: (1) to provide DNA, RNA, and tissue from neoplastic brain as well as DNA, RNA, tissue, and serum from normal blood, brain, and other body sites to programs and investigators within the SPORE, in a manner in which they can be used for a variety of studies and techniques under the oversight of the SPORE Tissue Committee; (2) to apply an integrated tissue bank/clinical data informatics system that allows the rapid identification of patient groups based on common demographics, clinical data, tissue diagnoses, and/or imaging studies and the efficient management and analysis of data from research results and clinical outcome under the oversight of a Tissue Committee; (3) to provide molecular genetic, molecular cytogenetic, and histologie analysis of banked samples in order to detect markers of classification, grading, and therapeutic response and to translate these findings into clinical trials with all projects in this SPORE. (4) to provide qualitative and quantitative assessments at the molecular, cellular, and histologic level of markers discovered in this SPORE for the translation of these basic discoveries into clinical trials. Initially we will characterize intratumoral and intertumoral heterogeneity and the diagnostic and prognostic significance of immunoreactivity for alkylguanine transferase (AGT), for the newly identified tumor glial cell surface markers MRP3, EGFR, and EGFRvIII, for glutathione S-transferase P1 (GSTP1) and for CMV antigen, pp65, in malignant human gliomas.

我们假设，围绕一个综合的组织学和分子诊断实验室组织的组织库，从不断更新的数据库中获得所有研究和临床信息，是该SPORE成功的基本要素。 为了验证这一假设，我们提出了以下四个具体目标： (1)在SPORE组织委员会的监督下，以可用于各种研究和技术的方式，向SPORE内的项目和研究者提供来自肿瘤性脑的DNA、RNA和组织以及来自正常血液、脑和其他身体部位的DNA、RNA、组织和血清; (2)应用集成的组织库/临床数据信息系统，该系统允许基于常见的人口统计学、临床数据、组织诊断和/或成像研究快速识别患者组，并在组织委员会的监督下有效管理和分析研究结果和临床结果的数据; (3)提供库存样本的分子遗传学、分子细胞遗传学和组织学分析，以检测分类、分级和治疗反应的标志物，并将这些发现转化为该SPORE中所有项目的临床试验。 (4)在分子、细胞和组织学水平上对该孢子中发现的标志物进行定性和定量评估，以便将这些基本发现转化为临床试验。首先，我们将描述肿瘤内和肿瘤间的异质性和诊断和预后意义的烷基鸟嘌呤转移酶（AGT），新发现的肿瘤胶质细胞表面标志物MRP 3，EGFR和EGFRvIII，谷胱甘肽S-转移酶P1（GSTP 1）和CMV抗原，pp 65，在恶性人类胶质瘤的免疫反应。